ANZBMS 2019
Chairs: Sue Lynn Lau & David Scott
Bone Health in Patients with Diabetes Mellitus (#69)
8:30 AM
Musculoskeletal health in low-middle income countries (#70)
9:00 AM
Optimising Bone Health in Cerebral Palsy (#71)
9:20 AM
Musculoskeletal Health of Aboriginal and Torres Strait Islander peoples (#72)
9:40 AM
T-score as an indicator of fracture risk on therapy: Evidence from Romosozumab vs Alendronate treatment in the ARCH trial (#73)
10:00 AM
Subject characteristics and changes in bone mineral density after transitioning from denosumab to alendronate in the denosumab adherence preference satisfaction (DAPS) study (#74)
10:12 AM